Accelerated versus standard epirubicin followed by CMF versus capecitabine as adjuvant therapy of breast cancer: results of the randomised UK TACT2 trial (CRUK/05/19)
| dc.contributor.author | Bliss, J | |
| dc.contributor.author | banerji, J | |
| dc.contributor.author | Gillman, A | |
| dc.contributor.author | Morden, J | |
| dc.date.accessioned | 2017-07-19T11:52:03Z | |
| dc.date.available | 2017-07-19T11:52:03Z | |
| dc.identifier.citation | The Lancet Oncology | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/710 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.relation.isreplacedby | internal/689 | |
| dc.relation.isreplacedby | https://repository.icr.ac.uk/handle/internal/689 | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
| dc.title | Accelerated versus standard epirubicin followed by CMF versus capecitabine as adjuvant therapy of breast cancer: results of the randomised UK TACT2 trial (CRUK/05/19) | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2017-05-10 | |
| rioxxterms.version | AM | |
| rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
| rioxxterms.licenseref.startdate | 2017-05-10 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | The Lancet Oncology | |
| pubs.declined | 2017-06-07T11:59:23.593+0100 | |
| pubs.deleted | 2017-06-07T11:59:23.593+0100 | |
| pubs.merge-to | internal/689 | |
| pubs.merge-to | https://repository.icr.ac.uk/handle/internal/689 | |
| pubs.notes | No embargo | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
| pubs.embargo.terms | No embargo | |
| icr.researchteam | Clinical Trials & Statistics Unit | |
| icr.researchteam | Clinical Trials & Statistics Unit | en_US |
| dc.contributor.icrauthor | Morden, James Peter | |
| dc.contributor.icrauthor | Bliss, Judith | |
| dc.contributor.icrauthor | Gillman, Alexa |
Files in this item
This item appears in the following collection(s)
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0